Iovance Biotherapeutics (IOVA) Price & Analysis

Compare

3,680 Followers

IOVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.64 - $12.51

Previous CloseN/A

Volume2.95M

Average Volume (3M)21.72M

Market Cap

$712.85M

Enterprise Value$327.34M

Total Cash (Recent Filing)$359.71M

Total Debt (Recent Filing)$53.72M

Price to Earnings (P/E)―

Beta2.16

Next Earnings

Nov 06, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding361,853,880

10 Day Avg. Volume19,137,652

30 Day Avg. Volume21,723,432

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)3.02

Price to Sales (P/S)13.07

P/FCF Ratio-5.89

Enterprise Value/Market Cap0.46

Enterprise Value/Revenue1.54

Enterprise Value/Gross Profit8.02

Enterprise Value/Ebitda-0.92

Forecast

1Y Price Target

$6.86

Price Target Upside248.22% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Regulatory ApprovalsAMTAGVI is on track for approval or regulatory submission in four ex-U.S. markets, including Canada, U.K., Australia, and Switzerland, which are significant commercial opportunities.

Strategic RestructuringIovance is entering a strategic restructuring estimated to save approximately $100 million annually, reduce cash burn, and improve gross margins without significant changes to the clinical pipeline.

Bears Say

Regulatory ChallengesIOVA withdrew its application to the EMA following lack of alignment during discussions on clinical data.

Revenue PerformanceThe stock was down approximately 35% in after-hours trading due to lackluster revenue and a lack of concrete catalysts or milestones in the near term.

Iovance Biotherapeutics News

Tesla disbands supercomputer team, Trade Desk Q2 spurs downgrades: Morning Buzz

The major averages were broadly higher near noon amid growing expectations that the Federal Reserve may move toward...

5d ago

Iovance Biotherapeutics price target lowered to $14 from $18 at Wells Fargo

Wells Fargo lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $14 from $18 and keeps an...

5d ago

IOVA

Iovance Biotherapeutics reports Q2 EPS (33c), consensus 928c)

Reports Q2 revenue $59.95M, consensus $67.14M. Frederick Vogt, Interim President and Chief Executive Officer of Iovance, stated, “In...

6d ago

IOVA

Iovance Biotherapeutics backs FY25 revenue view $250M-$200M, consensus $287.11M

The company said, “Iovance is reiterating total product revenue guidance within the range of $250 to $300 million...

6d ago

IOVA

Iovance Biotherapeutics options imply 23.8% move in share price post-earnings

Pre-earnings options volume in Iovance Biotherapeutics (IOVA) is 1.2x normal with calls leading puts 4:3. Implied volatility suggests...

6d ago

IOVA

Unusually active option classes on open July 23rd

Unusual total active option classes on open include: Beauty Health Co (SKIN), Krispy Kreme (DNUT), Wendy’s (WEN), Kirkland’s...

21d ago

RKT

Iovance Biotherapeutics appoints Roche as CFO

Iovance Biotherapeutics (IOVA) announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6th, 2025. Published...

29d ago

IOVA

Iovance Biotherapeutics downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs downgraded Iovance Biotherapeutics (IOVA) to Sell from Neutral with a price target of $1, down from...

29d ago

IOVA

H.C. Wainwright sees ‘impressive’ commercial data for Iovance’s Amtagvi

H.C. Wainwright reiterates a Buy rating on Iovance Biotherapeutics (IOVA) with a $20 price target after the company...

30d ago

IOVA

Iovance Biotherapeutics’ Earnings Call Highlights Growth

Iovance Biotherapeutics (($IOVA)) has held its Q2 earnings call. Read on for the main highlights of the call....

12h ago

IOVA

Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025

Iovance Biotherapeutics ( ($IOVA) ) has released its Q2 earnings. Here is a breakdown of the information Iovance...

5d ago

IOVA

Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Iovance Biotherapeutics. The associated price...

5d ago

IOVA

Iovance Biotherapeutics Reports Q2 2025 Financial Results

Iovance Biotherapeutics ( ($IOVA) ) has issued an announcement. Iovance Biotherapeutics reported its financial results for the second...

6d ago

IOVA

Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer

Iovance Biotherapeutics (($IOVA)) announced an update on their ongoing clinical study. Study Overview: Iovance Biotherapeutics is conducting a...

6d ago

IOVA

IOVA FAQ

What was Iovance Biotherapeutics Inc’s price range in the past 12 months?

Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $12.51 in the past 12 months.

What is Iovance Biotherapeutics Inc’s market cap?

Iovance Biotherapeutics Inc’s market cap is $712.85M.

When is Iovance Biotherapeutics Inc’s upcoming earnings report date?

Iovance Biotherapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 85 days.

How were Iovance Biotherapeutics Inc’s earnings last quarter?

Iovance Biotherapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.047.

Is Iovance Biotherapeutics Inc overvalued?

According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Iovance Biotherapeutics Inc pay dividends?

Iovance Biotherapeutics Inc does not currently pay dividends.

What is Iovance Biotherapeutics Inc’s EPS estimate?

Iovance Biotherapeutics Inc’s EPS estimate is -0.25.

How many shares outstanding does Iovance Biotherapeutics Inc have?

Iovance Biotherapeutics Inc has 361,853,880 shares outstanding.

What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?

Iovance Biotherapeutics Inc reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went down -20.076%.

Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?

Currently, no hedge funds are holding shares in IOVA

Iovance Biotherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-53.16%

Trailing 12-Months

Asset Growth

-5.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Iovance Biotherapeutics Inc

Iovance Biotherapeutics (IOVA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in tumor-infiltrating lymphocyte (TIL) therapy, an approach that harnesses the body's immune system to target and destroy cancer cells. Iovance is primarily engaged in the research, development, and commercialization of its lead product candidate, Lifileucel, which is designed for the treatment of metastatic melanoma and other solid tumors. The company operates in the biopharmaceutical sector, aiming to provide effective therapeutic options to patients with challenging cancers.

Iovance Biotherapeutics (IOVA) Earnings & Revenues

Historic Earnings Reports

IOVA Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment with strong revenue growth, positive clinical data, and strategic restructuring aimed at cost savings. However, challenges like increased expenses and an EMA submission withdrawal were noted.View all IOVA earnings summaries

IOVA Stock 12 Month Forecast

Average Price Target

$6.86

▲(248.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,4.012307692307693,5.344615384615385,6.676923076923078,8.00923076923077,9.341538461538462,10.673846153846155,12.006153846153847,13.338461538461539,14.670769230769231,16.003076923076925,17.335384615384616,18.66769230769231,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,3.0015384615384617,3.3230769230769233,3.644615384615385,3.966153846153846,4.287692307692308,4.609230769230769,4.930769230769231,5.252307692307692,5.573846153846153,5.895384615384615,6.216923076923077,6.538461538461538,{"y":6.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.550769230769231,2.4215384615384616,2.2923076923076926,2.163076923076923,2.033846153846154,1.9046153846153848,1.7753846153846156,1.6461538461538463,1.516923076923077,1.3876923076923078,1.2584615384615385,1.1292307692307695,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >